Study: High Psychotropic Medication Rates For Children With Autism

pills

STUDY: HIGH PSYCHOTROPIC MEDICATION RATES FOR CHILDREN WITH AUTISM

(Keep in mind as you read through this critical information that Autism is a condition of ELEVATED serotonin levels and nearly everyone of the medications Autistic children are being given are drugs designed to INCREASE serotonin levels thereby making the Autistic symptoms worse. Yet doctors are prescribing these drugs to 64% of Autistic children with everyone working to find ways to combat the symptoms of Autism while they are taking medications that make those symptoms worse!!! This also indicates that Adam Lanza, the shooter at Sandy Hook, had a 64% chance of being on one of these medications since he had a diagnosis of Autism.)

And research shows that mothers on antidepressants (all antidepressants increase serotonin) have a 3 to 4 times greater rate of having a child with Autism! Autism is only one of MANY birth defects associated with a mother’s use of antidepressants. To give one of those children additional drugs that increase serotonin levels after the initial exposure within the mother’s womb, thus giving the child no opportunity to recover from that initial exposure, is beyond criminal in my opinion!

The very first birth defect noticed in the offspring of children born to mothers on antidepressants was hypoglycemia which contributes to higher rates of seizures, attention-deficit disorders, anxiety, bipolar disorder, or depression. With that in mind read below about those being treated with multiple medications and higher odds of being medicated with these drugs are the ones showing symptoms of seizures, attention-deficit disorders, anxiety, bipolar disorder, or depression which indicates these are more likely those children who became Autistic due to their mother’s use of an antidepressant during pregnancy!!!

Disclaimer: Please do not attempt withdrawal or any change in dose without reading withdrawal information below!

THE STUDY OBJECTIVE AND RESULTS

OBJECTIVE: The objectives of this study were to examine rates and predictors of psychotropic use and multiclass polypharmacy among commercially insured children with autism spectrum disorders (ASD).

RESULTS: Among 33?565 children with ASD, 64% had a filled prescription for at least 1 psychotropic medication, 35% had evidence of psychotropic polypharmacy (=2 classes), and 15% used medications from =3 classes concurrently. Among children with polypharmacy, the median length of polypharmacy was 346 days. Older children, those who had a psychiatrist visit, and those with evidence of co-occurring conditions (seizures, attention-deficit disorders, anxiety, bipolar disorder, or depression) had higher odds of psychotropic use and/or polypharmacy.

CONCLUSIONS: Despite minimal evidence of the effectiveness or appropriateness of multidrug treatment of ASD, psychotropic medications are commonly used, singly and in combination, for ASD and its co-occurring conditions. Our results indicate the need to develop standards of care around the prescription of psychotropic medications to children with ASD.”Roughly two-thirds of children in the U.S. who are diagnosed with autism spectrum disorders (ASD) have been prescribed at least one psychotropic medication, according to new estimates published in the journal Pediatrics on Monday.

“In addition, 35 percent of the children were simultaneously prescribed two or more psychotropic medications, including antidepressants, attention deficit disorder medications and antipsychotics.

“Fifteen percent had been prescribed at least three different types of psychotropic drugs.

NO PROOF THESE DRUGS ARE SAFE IN CHILDREN

“I believe the takeaway is that children are on a lot of psychiatric medications without proof that they work or are safe in children,” study researcher Anjali Jain wrote in an email to The Huffington Post. Jain, a managing consultant with health care consulting firm Lewin Group, added that “nothing is known about what happens to effectiveness or safety when drugs are combined — or about long-term effects.”

Original article: http://www.huffingtonpost.com/2013/10/21/medication-autism_n_4136870.html

Link to study abstract: ttp://pediatrics.aappublications.org/content/early/2013/10/16/peds.2012-3774.abstract

WITHDRAWAL WARNING: In sharing this information about adverse reactions to antidepressants I always recommend that you also give reference to my CD on safe withdrawal, Help! I Can’t Get Off My Antidepressant!, so that we do not have more people dropping off these drugs too quickly – a move which I have warned from the beginning can be even more dangerous than staying on the drugs!

The FDA also now warns that any abrupt change in dose of an antidepressant can produce suicide, hostility or psychosis. These reactions can either come on very rapidly or even be delayed for months depending upon the adverse effects upon sleep patterns when the withdrawal is rapid! You can find the hour and a half long CD on safe and effective withdrawal helps here: http://store.drugawareness.org/
Ann Blake Tracy, Executive Director,
International Coalition for Drug Awareness
www.drugawareness.org & http://ssristories.drugawareness.org
Author: *”Prozac: Panacea or Pandora? – Our Serotonin Nightmare – The Complete Truth of the Full Impact of Antidepressants Upon Us & Our World” & Withdrawal CD “Help! I Can’t Get Off My Antidepressant!”

2,024 total views, 7 views today

Medical examiner confirms death of 9-yr-old Colony, TX boy was

NOTE FROM Ann Blake-Tracy (www.drugawareness.org):

This suicide is much too similar to little Gabriel Myers’ (7) suicide
in Florida last year – while in the custody of CPS! He too was on
similar medications when he impulsively hung himself with a shower
hose in the bathroom.

Both types of medications have an FDA black box warning for suicide
for this age group. WHY?!!! Want to talk about him being exposed to
something toxic? This is it! Why as a society do we allow this to
continue?!!! Why is it okay for doctors to give patients drugs that
could cause suicide?

Here is the warning given for Strattera which is prescribed for ADHD.
[And a similar warning was given to all antidepressant and mood
stablizing medications (which Montana was also taking).]

9/05 From Web MD: “The FDA is advising health care providers and
caregivers that children and adolescents being treated with Strattera
should be closely monitored for worsening of symptoms as well as
agitation, irritability, SUICIDAL THINKING OR BEHAVIORS, and unusual
changes in behavior, especially during the initial few months of
therapy or when the dose is changed (either increased or decreased).”

“THIS MONITORING SHOULD INCLUDE DAILY OBSERVATION BY FAMILIES AND
CAREGIVERS AND FREQUENT CONTACT WITH THE PHYSICIAN, says the FDA.”
[Emphasis added]

What kind of close monitoring is this when he hangs himself in a
nurses office?! Why did none of the professionals working with Montana
withdraw him from the medications which had been producing these
suicidal thoughts for some time BEFORE he lost his life? I see these
FAR TOO OFTEN and the children are getting younger and younger as
those who should be caring for them ignore these strong FDA warnings
that are the next closest thing there is to banning a group of drugs!

Ann Blake-Tracy, Executive Director,
International Coalition for Drug Awareness

http://www.dallasnews.com/sharedcontent/dws/dn/latestnews/stories/021710dnmetlancesuicide.12e83ee14.html?so=TimeStampAscending&ocp=5#slcgm_comments_anchor

Medical examiner confirms death of 9-year-old Colony boy was suicide

11:13 PM CST on Thursday, February 18, 2010

By WENDY HUNDLEY/The Dallas Morning News
whundley@dallasnews.com

The Tarrant County medical examiner’s office ruled Thursday that a
9-year-old boy from The Colony committed suicide.

Montana Lance

The determination rules out speculation that Montana Lance’s death was
an accident.

Montana was found hanging in a bathroom at Stewart’s Creek Elementary
School around 1 p.m. Jan. 21. He was taken to Baylor Medical Center at
Carrollton, where he was pronounced dead.

Lt. Darren Brockway of The Colony police said the medical examiner’s
ruling is consistent with police conclusions about the death.

“He’d gotten in trouble at school and panicked,” Brockway said. “He
just felt there was no other way out.”

There had been speculation that Montana watched a television show
about teen suicide the night before his death and was copying what he
saw with no real intention to kill himself.

“We ruled that out as an option after talking to his parents,”
Brockway said. “He didn’t watch that show.”

Also Online

01/25/10: Friends, family stunned by apparent suicide of 9-year-old boy

Link: Leave your condolences for the family of Montana Lance

Still, experts say children as young as Montana may not fully
comprehend the consequences of their actions. A suicidal act may be a
spur-of-the-moment act, like an outburst or a tantrum, they say.

“It was more of a conscious decision he made in a moment of high
anxiety,” Brockway said.

A spokesman for the Lance family could not be reached for comment
Thursday. A police report says Montana’s father had insisted the death
was accidental.

Brockway said Montana had been upset on the day of his death after he
was sent to the office for misbehaving in class. He locked himself in
the school nurse’s restroom and didn’t come out.

After about 10 minutes, the nurse got a key to open the door and found
the child unconscious.

Montana had attached the buckle of a brown cloth belt to a hook of a
device used to help disabled people use the restroom, according to a
police report. He was found with the belt around his neck with his
feet off the floor. Police found no notes or messages.

He had been taking medication for mood swings and for attention
deficit hyperactivity disorder, and had been having suicidal thoughts
for about two years, the police report states.

In 2007, Montana’s parents, Jason and Debbie Lance, sought treatment
for their son for ADHD.

In 2008, they told the doctor that the boy had been talking about
committing suicide, and he was referred to a psychiatrist, according
to the police report.

After Montana’s death, Child Protective Services opened an
investigation to determine whether abuse or neglect were contributing
factors.

That investigation has not been completed, but the family’s other two
children have not been removed from the home, CPS spokeswoman Marissa
Gonzales said.

Gonzales said CPS has had no prior involvement with the Lances and
routinely investigates child fatalities.

With the medical examiner’s ruling, police plan to close their
investigation with no charges filed, Brockway said.

549 total views, 1 views today

DEPRESSION MED: 14 Year Old Girl Attempts Suicide in School During Class…

Paragraph four reads:  “The victim’s mother said her
daughter
takes medication for ADHD and
depression.”

http://chronicle.augusta.com/stories/latest/lat_703887.shtml?v=1642

Middle school student attempts suicide during class
Stephanie
Toone | South Carolina Bureau Chief
Thursday, Dec. 10, 2009 4:42
p.m.

GRANITEVILLE – A Leavelle McCampbell Middle School student tried
to commit suicide in a classroom Wednesday by overdosing on prescription drugs.


An art teacher at the middle school on Canal Street said the 14yearold
took close to 50 pills during class around 8:15 a.m. in an attempt to kill
herself, according to an Aiken County Sheriff’s Office report. The student was
transported to Aiken Regional Medical Center’s emergency room, but there were no
details on her condition.

Two students told investigators that the
student said she was going to take her “death pills,” then swallowed the
cocktail of prescription drugs, according to the report.

The victim’s
mother said her daughter takes medication for ADHD and depression.


Cecelia Davidson, associate superintendent for administration, said she
was not aware of the incident, but said the guidance and principal staff has
protocol for suicide threats or attempts.

From the Thursday, Dec. 10,
2009 online edition of The Augusta Chronicle

494 total views, 1 views today

Over 81% Took An Antidepressant or ADHD Med Before Being Diagnosed Bipolar

WOW!! This certainly makes the connection between the use of these drugs and Bipolar Disorder obvious! But is this suppose to be a big surprise?!

From my new DVD, Bipolar, Shmypolar, Are You Really Bipolar or Misdiagnosed Due to the Use of or Abrupt Discontinuation of an Antidepressant?, let me give you a quick synopsis.

An ANTI-depressant is the opposite of a depressant and is what?

That is correct. It is a stimulant.

What is bipolar? It is a continuous series of mild seizures.

What produces seizures? STIMULANTS, like antidepressants and amphetamines – Ritalin, etc.!

Chemically inducing Bipolar Disorder to create a whole new customer base for the new and high priced atypical antipsychotics is not the least bit difficult when you start patients out on stimulant medications, like Ritalin and antidepressants. That is especially true when given to a young patient with yet growing and developing, and therefore more vulnerable, brain!

Ann Blake-Tracy, Executive Director,
International Coalition for Drug Awareness
www.drugawareness.org & www.ssristories.drugawareness.org
Author: Prozac: Panacea or Pandora? Our
Serotonin Nightmare and audio: Help! I Can’t
Get Off My Antidepressant ()

Sixth sentence reads: “During the year before the new diagnosis of bipolar disorder, youths were commonly diagnosed as having depressive disorder (46.5%) or disruptive behavior disorder (36.7%) and had often filled a prescription for an antidepressant (48.5%), stimulant (33.0%), mood stabilizer (31.8%), or antipsychotic (29.1%].”

http://psychservices.psychiatryonline.org/cgi/content/abstract/60/8/1098

Psychiatr Serv 60:1098-1106, August 2009
doi: 10.1176/appi.ps.60.8.1098
© 2009 American Psychiatric Association

Article

Mental Health Treatment Received by Youths in the Year Before and After a New Diagnosis of Bipolar Disorder
Mark Olfson, M.D., M.P.H., Stephen Crystal, Ph.D., Tobias Gerhard, Ph.D., Cecilia S. Huang, Ph.D. and Gabrielle A. Carlson, M.D.

Dr. Olfson is affiliated with the Department of Psychiatry, Columbia University, New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032 (e-mail: mo49@columbia.edu ). Dr. Crystal and Dr. Huang are with the Institute for Health, Health Care Policy, and Aging Research, and Dr. Gerhard is with the Ernest Mario School of Pharmacy, both at Rutgers University, New Brunswick, New Jersey. Dr. Carlson is with the Department of Psychiatry and Behavioral Medicine, Stony Brook University School of Medicine, Stony Brook, New York.

OBJECTIVE: Despite a marked increase in treatment for bipolar disorder among youths, little is known about their pattern of service use. This article describes mental health service use in the year before and after a new clinical diagnosis of bipolar disorder. METHODS: Claims were reviewed between April 1, 2004, and March 31, 2005, for 1,274,726 privately insured youths (17 years and younger) who were eligible for services at least one year before and after a service claim; 2,907 youths had new diagnosis of bipolar disorder during this period. Diagnoses of other mental disorders and prescriptions filled for psychotropic drugs were assessed in the year before and after the initial diagnosis of bipolar disorder. RESULTS: The one-year rate of a new diagnosis of bipolar disorder was .23%. During the year before the new diagnosis of bipolar disorder, youths were commonly diagnosed as having depressive disorder (46.5%) or disruptive behavior disorder (36.7%) and had often filled a prescription for an antidepressant (48.5%), stimulant (33.0%), mood stabilizer (31.8%), or antipsychotic (29.1%). Most youths with a new diagnosis of bipolar disorder had only one (28.8%) or two to four (28.7%) insurance claims for bipolar disorder in the year starting with the index diagnosis. The proportion starting mood stabilizers after the index diagnosis was highest for youths with five or more insurance claims for bipolar disorder (42.1%), intermediate for those with two to four claims (24.2%), and lowest for those with one claim (13.8%). CONCLUSIONS: Most youths with a new diagnosis of bipolar disorder had recently received treatment for depressive or disruptive behavior disorders, and many had no claims listing a diagnosis of bipolar disorder after the initial diagnosis. The service pattern suggests that a diagnosis of bipolar disorder is often given tentatively to youths treated for mental disorders with overlapping symptom profiles and is subsequently reconsidered.

Related Article:
August 2009: This Month’s Highlights Psychiatr Serv 2009 60: 1009. [Full Text] [PDF]

678 total views, 1 views today

ANTIDEPRESSANT: Psychiatrist Goes Nuts: Diagnosed Bipolar as They All Are!

Paragraphs 6 through 9 read: “Munn lost his license to practice psychiatry in Montana in 2003, after having an ongoing sexual relationship with one of his patients. His marriage dissolved around the same time. Already being treated for depression, Munn’s condition was rediagnosed, and with the help of counseling and medicine, he rebuilt his life into one where he’s succeeding while living with a mental illness.”

“Anti-depressants didn’t help the manic side of Munn’s bipolar disorder. At times his thoughts raced. He didn’t sleep. He had grandiose ideas ­ like how to fix the entire mental health system in the state of Montana.”

“And he believed he could do anything he wanted.”

“’I felt rules didn’t apply to me. That would be grandiosity,’ he said. ‘But they do. And that’s accepting that you have a mental illness’.”

http://www.helenair.com/articles/2009/08/02/top/55lo_090802_mh2.txt

Psychiatrist brings himself back from the brink of suicide

By JOHN HARRINGTON – Independent Record – 08/02/09

Eliza Wiley Independent Record – Nathan Munn has fought back from some very low places. Rather than ending his life, the psychiatrist chose to seek treatment for his bipolar disorder and began a new career teaching psychology courses and developing a mental health direct care program at University of Montana-Helena.
In 2003, with his career and home in very public shambles, Nathan Munn nearly committed suicide.

But rather than end his life, the psychiatrist chose not to pull the trigger one fateful night. He subsequently got treatment, including psychotherapy and medications, for his bipolar mood disorder.

Now, Munn is an instructor at the University of Montana-Helena, teaching psychology courses and developing a mental health direct care program that trains students how to be direct caregivers, counselors and other types of mental health professionals.

“I’m really thankful for my job at UM-Helena,” said Munn, 49, in a candid interview last week. “And I hope that my story can be of some inspiration along with my teaching. It’s my intention that I’m still helping in the community, but now with education as opposed to direct providing of psychiatric care.”

Munn admits somewhat nervously that his past is still “hard to talk about.” He chooses his words carefully, often pausing between sentences. He’s told his humbling story before, and maybe it’s getting a little easier ­ but not much. Remorse hangs deep in his eyes.

Munn lost his license to practice psychiatry in Montana in 2003, after having an ongoing sexual relationship with one of his patients. His marriage dissolved around the same time. Already being treated for depression, Munn’s condition was rediagnosed, and with the help of counseling and medicine, he rebuilt his life into one where he’s succeeding while living with a mental illness.

Anti-depressants didn’t help the manic side of Munn’s bipolar disorder. At times his thoughts raced. He didn’t sleep. He had grandiose ideas ­ like how to fix the entire mental health system in the state of Montana.

And he believed he could do anything he wanted.

“I felt rules didn’t apply to me. That would be grandiosity,” he said. “But they do. And that’s accepting that you have a mental illness.”

Mental illnesses are by no means limited to those on the fringes of society. Millions of Americans of all walks of life ­ blue collar and white, laborers and professionals ­ live daily with schizophrenia, depression, bipolar mood disorder and other diagnosable and treatable conditions.

Mike Larson of Dillon is director of the State Bar of Montana’s Lawyer Assistance Program, which was created in 2006 after several attorneys committed suicide in Missoula.

“Lawyers, from the first call in the morning to the last e-mail at night, are busy dealing with everyone else’s problems,” Larson said. “So what do they do when their own problems kick in?”

Larson said that from a population of 2,800 members of the bar in Montana, he takes calls from eight to 10 new clients a month, around a third of which are related to mental illness, with another third dealing with chemical dependency. He said many lawyers are reticent to call the program, either out of fear that others will learn of their treatment and their careers will suffer, or from simple denial.

“There are a lot of stereotypes out there about what mental illness is, and there’s that whole component of not wanting to be under the stigma of mental illness,” Larson said.

For Munn, day-to-day life means a regimen of a mood-stabilizing drug and an anti-depressant, acknowledgement of and taking responsibility for the mistakes he made and a resolve to move forward knowing the illness will likely be with him for the rest of his life.

“It’s not like there’s one day that you no longer have a mental illness,” he said. “On appropriate treatment, it can be in remission. And you stay on your meds and you do the psychological work necessary, and you move forward.

“I hate to say it because it sounds like it’s bragging, but it takes courage. You have to face this, you face what you did, you face having a mental illness, and you accept other aspects of your life.”

Munn doesn’t hide from his condition, and hopes that sharing his story will comfort others who find themselves in similar positions.

“One of the main things I want to say is when you have a mental illness, you have to acknowledge that that’s there, and that you have it,” he said. “I have a bipolar disorder, I am not bipolar. It is something that I have, it is not something that I am. A lot of people say, ‘I am bipolar.’ Well, what does that mean? You don’t say, ‘I am congestive heart failure. I am sinusitis.’ It’s not who you are, it’s what you have.”

Just as there are ways to characterize people living with mental illness, there are productive ways to discuss the illnesses themselves, Munn said.

“(People) talked about the dark recesses of the mind. That’s not the way to talk about it,” he said. “The term ‘dark recess’ has such a negative connotation, Dr. Jekyll and Mr. Hyde, that’s not it. They’re not dark recesses. It’s neuropathology. It’s limbic system disregulation. And it’s the cognitions, the thinking that goes along with it.

“That’s a tough thing for people to get, but I think it’s crucial for people to get that as they’re recovering from a mental illness, that our brains and our minds are the same thing. So when I have negative cognitions, when I’m thinking that people would be better off without me, that’s the psychological part.

“And that’s a key point for people, is that what you’re thinking psychologically and what your brain is doing physically, we don’t know how it’s the same function, but it is the same function. The subjective psychology that you’re feeling as a person with a mental illness, is the psychological aspect of the biological process, and yes, it is a real illness. The idea that a psychological illness is somehow not real is just absurd. That’s crazy.”

Many mental illnesses can be directly traced to chemical imbalances or other physical abnormalities in the brain. But having a mental illness can’t by itself be an excuse for any actions, good bad or otherwise.

“You don’t want to use it as an excuse to justify behaviors. You have to take accountability. Personal accountability is necessary for recovery, it just is,” he said. “It takes humility, it takes a lot of work, it takes compliance.

“I made huge mistakes. My choices were horrible. Despicable, really, is the term to use. I hurt a lot of people. I hurt patients that I had, the person herself and her family, and of course my family. I feel sorry and apologetic about that every day. Especially for my children, I feel horrible and always will.

“One of the points I would like to make is, yes, I have this bipolar disorder. To deny I do would be to deny I have a mental illness. But I also completely accept responsibility and accountability for my actions. And that’s a very important point: recovery requires personal accountability. Yes, I have a major mental illness, and yes, I am responsible for my actions. Those aren’t mutually exclusive.”

Treating a mental illness isn’t a guarantee of happiness. Life still presents challenges, and treatment gives those suffering from mental illness a better chance at facing those challenges head-on and coming out ahead.

“Life has struggles, with or without a mental illness,” Munn said. “Having your mental illness treated doesn’t mean your life is wonderful. You’re still going to have the struggles that everyone has. But you’ll also have wonderful things. I’m a grandfather. And that’s wonderful. If I had killed myself, I wouldn’t have known this joy of having a granddaughter.

“You have to accept mental health care of various types, and you need to know that it’s worth it, that treatments are available, the science is there, people do recover, illnesses do go into remission. Of all chronic illnesses to have, having a mental illness is not bad. Treatments are available, and you can live a long, good life having your mental illness treated.”

Larson of the Lawyer Assistance Program acknowledged that people need to want to treat their illnesses.

“There are a lot of people out there that still need the help that haven’t come forward or recognized they need the help,” Larson said. “Not only are they in denial that they have a problem, they’re in denial that everyone knows they have a problem.”

And even if the disease goes into remission or becomes manageable, a person must be diligent, even when things are going well.

“It’s not something you mess around with. And that’s OK,” Munn said. “Mental illnesses are chronic illnesses. People have the idea that, ‘Oh no, I’m going to be on medications for life.’ Well yeah, you are. And that’s all right, you have a chronic illness. There are a lot of chronic illnesses, not just psychiatric ones. And people who have those, like type 1 diabetes, will be on insulin. It’s accepted. So it’s a chronic illness, you accept that.”

And the more acceptance there is, across a broader swath of Montana at large, the easier it will be for people to summon the strength to get the help they need, to confront the illness, and to assume the places so many of them deserve as productive members of society.

To view the complete series on mental health care services in Montana, click here.

John Harrington: 447-4080 or john.harrington@helenair.com.

549 total views, no views today

ZOLOFT, PROZAC, Adderall & Ritalin: 18 Year Old Shoots Deputy: Critcal …

WHEN ARE DOCTORS EVER GOING TO REALIZE THAT THEY CANNOT GIVE ALL OF THESE DRUGS TOGETHER?!!!!!!! THERE IS NO CLINICAL DATA TO PROVE THE SAFETY OF EVEN TWO OF THEM GIVEN IN COMBINATION!!!!!!!!!!!!!!!!!!!

Paragraphs 11 though 14 read: “To combat attention disorders and other conditions, the teen took Ritalin, Zoloft, Prozac and Adero, among other drugs, Bryce said, toting the various prescriptions with him in a pill sorter.”

“The medicine sedated Adrian for hours. He was often unresponsive and seemingly unaware of people talking to him while on the medication, Bryce said.”

“The assortment of pills ‘took a toll on him,’ he said.”

“Other times Adrian displayed anger he seemed unable to control, Bryce said. Some of it was typical teen behavior, but sometimes Adrian “blacked out” and later forgot about the episodes, Bryce said.”

http://www.dailycomet.com/article/20090731/ARTICLES/907319905/-1/SPORTS12?Title=Dad-says-There-s-something-wrong-with-him –

Dad says, ‘There’s something wrong with him’

Father grieves for son suspected of shooting deputy.
By Matthew Pleasant
Staff Writer

Published: Friday, July 31, 2009 at 12:24 p.m.
Last Modified: Friday, July 31, 2009 at 12:24 p.m.

BOURG ­ To understand what happened, Bryce Broussard sifts through memories of his son.
Related Links:

He cries as he remembers an 18-year-old boy who struggled to read, who needed help filling out job applications and had an unpredictable and explosive temper, he said.

The same young man earned money by cutting Hope Street yards, who welded his own workout bench in school and sometimes fell asleep wearing headphones.

The teen, Adrian Broussard, is now charged with attempted first-degree murder, accused of shooting Terrebonne deputy David Bourg three times Tuesday and leaving him in critical condition.

Still reeling over the arrest, Bryce, 36, said he and his wife, Amy, plan to support his son. He finds it hard to comprehend Adrian committing the crime, he said, but recognizes the behavior problems that may have contributed to the shooting.

“He was a good kid, but there’s something wrong with him,” said Bryce, an offshore worker. “He would blow up over nothing.”

Adrian Broussard’s last steady home was 128 Hope St. in Bourg, where his father said Adrian lived for two years before moving to live with a relative in Montegut.

He struggled through school at South Terrebonne High to earn a technical-skill degree, Bryce said. Rusting in the yard is a workout bench and frames for four-wheelers ­ all of it Adrian’s work.

Often unable to concentrate, Adrian took a slew of medications, his father said. But he never seemed more focused or content than when welding or dissembling a motor.

“He wanted to make different things that nobody else had,” Bryce said.

To combat attention disorders and other conditions, the teen took Ritalin, Zoloft, Prozac and Adero, among other drugs, Bryce said, toting the various prescriptions with him in a pill sorter.

The medicine sedated Adrian for hours. He was often unresponsive and seemingly unaware of people talking to him while on the medication, Bryce said.

The assortment of pills “took a toll on him,” he said.

Other times Adrian displayed anger he seemed unable to control, Bryce said. Some of it was typical teen behavior, but sometimes Adrian “blacked out” and later forgot about the episodes, Bryce said.

His unwieldy behavior and penchant for mechanic work followed the family to Disney World last summer, where the teen preferred to stay at the hotel rather than visit the parks, they said. When the family truck broke down, he worked on it without hesitation.

The father and son bought parts and repaired the truck in the hotel parking lot, he said.

“He helped me piece by piece, tearing it down,” he said.

Bryce said the family tried to help him find a job after graduation. The family ate at Golden Corral during one trip into Houma, and Adrian’s temper flared at servers who told him the restaurant wasn’t serving steak.

He berated the kitchen staff, telling them none knew how to cook, Bryce said. He also threw his cup in the dining room, sending drink all over surrounding tables.

“It was nothing nice,” he said.

Neighbors said the Broussard family seemed to have a troubled home life, citing fights and police visits to the trailer. Bryce and Amy Broussard said they were close despite the incidents.

“We’re not saying we’re perfect,” Amy Broussard said.

Adrian Broussard left the Hope Street trailer several months ago to stay with cousins in Montegut and only occasionally spent time with his father after that, Bryce said.

Just before midnight Tuesday, Adrian allegedly gunned down a deputy investigating reports of a suspicious person outside the Montegut Post Office.

By 1 a.m. Wednesday, deputies were at the Broussard’s trailer demanding to know where Adrian was, Bryce said. He said he spent much of the morning handcuffed inside a police cruiser that drove through Montegut in search of the teen.

The elder Broussard was charged that day with simple criminal damage to property and theft of goods over $500, according to jail records. Broussard said the arrest stemmed from outstanding warrants.

Adrian was arrested about 12 hours after the shooting when a resident found him inside an abandoned home, police have said. He is being held at the Terrebonne Parish jail in lieu of a $2 million bond on the attempted first-degree-murder charge. He is also charged with simple burglary, trespassing, possession of marijuana and illegal carrying a weapon, deputies said.

Deputies had searched for Adrian Broussard earlier Tuesday to arrest him on warrants for felony theft and criminal damage. His bond for the warrant charges is $20,000.

Deputy Bourg, a five-year veteran of the Sheriff’s Office who is married with children, remains in stable condition in the critical care unit at Terrebonne General Medical Center.

While Bryce is hoping for the best outcome for his son, he says he also hopes Bourg is able to heal.

“We are praying for a full recovery,” Bryce said. “We apologize to the family, and we’re very sorry for what happened.”

Staff Writer Matthew Pleasant can be reached at 857-2202 or matthew.pleasant@houmatoday.com.

534 total views, no views today

Strattera Deaths (German TV Request) False Reports from Eli Lilly

Wed Nov 12, 2008

We have received a request from a German TV crew who is doing a special on Lilly’s newer ADHD medication, Stratera. These investigative reporters from Germany are doing a 45 minute piece and looking for experiences of tragedy /suicide or severe adverse reactions in children treated for ADHD with this drug. I know we have had reports, but I do not keep close track anymore of which drug is involved after so many cases because all these drugs work basically the same way. An antidepressant is an antidepressant no matter what you callmit or what you prescribe it for or how you explain its supposed uniqueness. So if you or someone you know has been through a Strattera-induced nightmareand would be willing to help get some exposure of this in the press, please get in touch with me so that I can put you in touch the reporters.

O nce you read the following article on Strattera deaths you will see how very important it is to get information about this drug out to the public –

especially throughout the UK and Europe. What is going on here IS CRIMINAL!!
And here is just one example out of the article below that is full of data on how
the government agency in the UK who oversees these drugs is ignoring
critical information – even fatalities, and doing NOTHING but making excuses
for their own behavior:

MHRA has for almost three years been in possession of data showing that
Strattera in many cases actually can cause or worsen the œcondition it is
claimed to alleviate. More than 700 reports were submitted to the manufacturer,
Eli Lilly, about Strattera inducing “œpsychomotor hyperactivity. Lilly called
this an exacerbation of the “œunderlying ADHD”. If we would apply this to
the area of real medicine and to diabetes we could say that the patient got a
diabetes medication with resulting heavy increase in blood sugar level. Such a
medication would probably be withdrawn very fast from the market. But the
MHRA has not yet, after three years, succeeded to get even a bad quality review
of these cases done not even from the manufacturer.

Do read the rest of the information because it is clearly eye opening!! This
newer ADHD drug, Strattera, which is really an SSRI antidepressant, is
getting away with murder right under everyone’s noses. So definitely if you
know someone who is willing to talk to this news crew about their experience with
this drug, please do let me know ASAP.

Thank you,

Ann Blake-Tracy, Executive Director,
International Coalition for Drug Awareness
_www.drugawareness.org_ (http://www.drugawareness.org/) &
_www.ssristories.org_ (http://www.ssristories.org/)
Author of Prozac: Panacea or Pandora? – Our
Serotonin Nightmare & the audio, Help! I Can’t
Get Off My Antidepressant!!! ()

_atracyphd1@…_ (mailto:atracyphd1@…)

_http://www.newmediaexplorer.org/sepp/2008/10/20/strattera_adverse_effects_uk_
medicines_agency_refuses_to_act.htm#_
(http://www.newmediaexplorer.org/sepp/2008/10/20/strattera_adverse_effects_uk_me\
dicines_agency_refuses_to_act.htm#
)

October 20, 2008
_Print this article_
(http://www.newmediaexplorer.org/sepp/2008/10/20/strattera_adverse_effects_uk_me\
dicines_agency_refuses_to_act.htm#
)

Strattera adverse effects: UK Medicines Agency refuses to act
By Sepp Hasslberger

Categories
_Pharma_ (http://www.newmediaexplorer.org/sepp/pharma.htm)

Janne Larsson, an investigator and reporter in Sweden, has obtained
information about adverse event reports on Eli Lilly’s ADHD drug Strattera,
using the Swedish freedom of information laws. The data, coming from both the FDA’s
adverse reaction database and from reports to the UK’s Medicines agency, shows
numerous adverse effects and scores of deaths by suicide.

Yet the agency, even after repeated prodding by Larsson to initiate action,
has refused to budge or even acknowledge that there is a problem. MHRA
apparently accepts the drug’s producer Eli Lilly’s data rather than its own and
the
FDA’s adverse event reports.

Image credit: _Monheit Law_
(http://www.monheit.com/strattera/contact_lawyer.asp)

Larsson says: An investigation of MHRA™s handling of the harmful effects of
the ADHD drug Strattera has proven the following:

MHRA has ignored data about instances of death among children in connection
with Strattera treatment. At least 41 children have died. The agency has not
investigated the reported cases and does not even have a compiled summary of
cases with fatal outcome. Further the agency has allowed the manufacturer Eli
Lilly to give false information about the number of fatal cases and has
taken no action against the company once the false information was revealed.

MHRA has for almost three years been in possession of data proving that
Strattera can cause agitation, mania and psychotic reactions with hallucinations
among children. Yet no warning has been issued to doctors and parents. The
agency has withheld these disastrous consequences despite clear evidence. Due
to bureaucratic procedures no warnings have been issued even if Eli Lilly reluc
tanly conceded to include these harmful reactions in its information to the
public almost a year ago.

MHRA has for almost three years been in possession of data showing that
Strattera in many cases actually can cause or worsen the œcondition it is
claimed to alleviate. More than 700 reports were submitted to the manufacturer,
Eli Lilly, about Strattera inducing œpsychomotor hyperactivity. Lilly called
this an exacerbation of the œunderlying ADHD. If we would apply this to
the area of real medicine and to diabetes we could say that the patient got a
diabetes medication with resulting heavy increase in blood sugar level. Such a
medication would probably be withdrawn very fast from the market. But the
MHRA has not yet, after three years, succeeded to get even a bad quality review
of these cases done“ not even from the manufacturer.
The background data for these conclusions can be found in the following text
and in the linked documents. When reading the data below please remember the
promise from the MHRA: we take any necessary action to protect the public
promptly if there is a problem._MHRA, About us_
(http://www.mhra.gov.uk/Aboutus/index.htm) [1]

Note that the linked documents (within letters described below) in most
cases could not be obtained in UK where the issuance of them would be deemed as
prejudicing œthe ability of the Assessory body to offer impartial advice and
where the MHRA wants to allow marketing authorisation holders the chance to
respond to regulatory action and make commercial decisions before data are
in the public domain. (MHRA, e-mail about FOIA-request, 29th September,
2006). However the documents could be obtained in Sweden, even if the MHRA has
tried to stop the issuance of them by implying that publication could threaten
the relations between Sweden and UK.
Deaths among children in connection with Strattera treatment

In May I submitted detailed data about cases of Strattera death to the MHRA.
1st October I finally got an answer from the Scientific Assessor of the
Vigilance and Risk Management of Medicines (VRMM). 7th October I got an answer
from Professor Kent Woods, CEO of the MHRA, referring to the letter sent by the
Scientific Assessor.

My data about Strattera deaths can be found _in the letter_
(http://jannel.se/Strattera.death2.pdf) Strattera: Eli Lilly gave false
information about
deaths from Strattera treatment “ a request for full investigation from 15th
May. [2]
The answer from the Scientific Assessor shows that MHRA is continuing to
ignore data about instances of death among children and adults in connection
with Strattera treatment. Despite limited resources and having to rely on data
released by reluctant medical agencies I had been able to produce a summary of
reported cases of Strattera death. Thats much more than the MHRA, with its
immense resources, had been able to do.

The agency was provided with specific data about instances of death forming
an excellent starting point for a full investigation. But instead of using
the data the MHRA used its energy to explain why it is impossible to
investigate these cases further, and in doing so presents some remarkable
comments.

The Scientific Assessor states _in the letter 1st October_
(http://jannel.se/Reply.from%20MHRA.Assessor.October.pdf) [3]:

in order to calculate the total number of reports with a fatal outcome
it is not simply a case of adding up reports with a fatal outcome mentioned
in our assessment reports of the PSURs [Periodic Safety Update Reports] and
those available on the FDA website as these different sources may contain
duplicate information. [Emphasis added.]

I fully agree and it takes only a casual reading of my letter from 15th May
to find out that much care has been taken to exclude possible duplicates. It
is quite easy to see that the data presented about fatal cases in my letter
is NOT simply a case of adding up reports with a fatal outcome. The only
way to come to another conclusion would be not to look in the first place and
it is a condemnation of the effectiveness of the agency to state the following
in the letter:

We have looked at the data you have sent us to see if they can add insight
to the statutory sources of data we have received and do not think that they
are of benefit as we cannot verify their source or accuracy. (p. 3)
[Emphasis added.]

I must add to all the data provided in my letter 15th May that the our

of the information about fatal cases is FDA™s Medwatch system and the PSURs
(submitted directly to the MHRA). I must make it clear that is very easy for
a lay person to find out that almost all reports about fatal outcome from
Strattera treatment submitted to the FDA came from Eli Lilly!

Thus the our of the information about fatal cases was in most of the
cases the manufacturer itself“ Eli Lilly. And yet the MHRA has not been able
to verify the source or accuracy of the information. The MHRA Scientific
Assessor states in the letter:The sources of data that regulators use such
as company data, spontaneous adverse reaction reports and literature are set
out in European and national law.
My FOIA request earlier this year to get a compilation of fatal cases in
connection with Strattera treatment was answered 12th August:

Thats very good and now we know that the data I submitted to the MHRA about
all fatal cases from Strattera treatment “ in the absolute majority of cases
were known by and reported via the manufacturer Eli Lilly.
The MHRA holds no data other than that previously released to you [the
misleading data from Eli Lilly in November 2007, see my letter from 15th May
for
more data] which was the data provided by the company. If you have any
questions about FDA data or the data provided by the company, you should
contact those organisations.

In other words the MHRA didn’t have a compiled summary of cases with fatal
outcome in August and the agency has not to this point been able to compile
such a summary.

As the agency has not been capable of getting the data or not even been
capable of using the specific data submitted for its use in a full
investigation NO action is taken despite the many verified deaths among
children in connection with Strattera treatment. This disregard for the safety of children is a scandal which should lead to a full formal investigation by the
Department of Health.

Drug induced agitation, mania and psychosis with hallucinations

Ive been contacted by parents asking if Strattera can induce mania and
psychosis with hallucinations. Their children have had such symptoms. The
parents have not found any warnings about it and their childrens doctors don’t
think that the symptoms are caused by the drug. The parents were desperate.

However the MHRA has known for almost three years that Strattera can cause
agitation, mania and psychotic reactions with hallucinations among children,
but has refused to issue warnings about it.

The Scientific Assessor from the MHRA _in the letter of 1st October_
(http://jannel.se/Reply.from%20MHRA.Assessor.October.pdf) [3] now confirms my
earlier arguments that the agency had knowledge about these effects a long time ago:

following an initial request in the assessment report for the Periodic
Safety Update for the period (dates 27-05-2005 to 26-11-2005) we asked Eli
Lilly for more information to enable us to review this issue in more detail. (p. 2)

This means that in the period ending 26th November, 2005 at the time when
Strattera was approved only in UK and four other European countries, but not
in the 22 additional European countries where it is now approved Eli Lilly
and the MHRA had knowledge about these disastrous effects in children taking
Strattera. But neither the MHRA nor Eli Lilly told anything about it and
Strattera was approved in 20 additional European countries in April 2006.
Image credit: _Wikimedia Commons_
(http://commons.wikimedia.org/wiki/Image:Strattera_atomoxetin.jpg)

Professor Kent Woods, CEO of the MHRA seems to be very misinformed by his
staff when answering about Strattera in a recent _letter of 7th October, 2008_
(http://jannel.se/answer.kent.woods.pdf) . In the letter Professor Woods
states [4]:

The MHRA is committed to ensuring that all safety concerns are subject to
robust scientific assessment and the best possible regulatory action is taken
in a timely manner. We strive to maintain the highest standards of work and
review our practices to ensure these standards are maintained or improved
upon where necessary. (p. 1)

In their 3rd March, 2006 report Psychiatric Adverse Events Associated with
Drug Treatment of ADHD: Review of Postmarketing Safety Data [5], the FDA
stated that there was compelling evidence for a likely causal association
between [Strattera/amphetamine drugs] and treatment emergent onset of signs and/or
symptoms of psychosis or mania, notably hallucinations, in some patients.

(p. 17) 360 reports about the drug inducing these effects had been received
up to June 2005.

From this FDA report the MHRA had knowledge about the œcompelling evidence for Strattera causing these effects on or about 3rd March, 2006 but did nothing.

In August the same year (2006) the MHRA requested the same data set from Eli
Lilly that was submitted to the FDA and which formed the basis of the FDA
report for Strattera. The data was sent to the MHRA some days later. But the
agency then decided not to do anything with the information. Instead it was
decided that Eli Lilly the manufacturer should do an analysis of the data
and submit its conclusions to the agency.

Professor Kent Woods says in his letter: An important aspect to this [ robust scientific assessment, highest standards] is ensuring that data from all available sources have been consider This may be true in some other area but it is definitely not true for the
safety work around Strattera. A very good example of this is the complete
rejection of the robust scientific assessment of Strattera in the FDA report.
Answering the question why the agency did not use the compelling evidence for harm in the FDA report _an official at the MHRA declared in a letter_
(http://jannel.se/mhraanswer.pdf) [6]:

Changes to European product information are based on assessment by EU
regulators, agreement between member states and in line with legal requirements
about product information, not on conclusions of FDA assessors. (25th May,
2007) [Emphasis added.]

Responsible officials at the MHRA had instead decided to rely completely on
the analysis of the manufacturer of the drug Eli Lilly. (In an article in
the Daily Mail this summer, Andrew Herxheimer, editor of the Drug and
Therapeutics Bulletin, and emeritus fellow of the Cochrane Centre commented:
Asking a drug company to review its own product is crazy, but it goes on quite a lot.
) [7]

At the end of 2007/beginning 2008 Eli Lilly submitted its review of
Strattera induced agitation, mania and psychosis with hallucinations to the
MHRA. It was a complete whitewash.

In summary: FDA was very clear about the psychosis-inducing effects of
Strattera; the MHRA did not listen. Instead the MHRA turned to the
manufacturer. Eli Lilly tried to explain away all the bad results found in its review. For
the full history about MHRA’s failure in this area and for a comparison of
the FDA report with the Lilly report, please see the following letter: _The
ADHD drug Strattera“ actions needed now_
(http://jannel.se/letter.mhra.strattera.jan08.pdf) [8] from January 2008, and
the letter _The ADHD drug Strattera“
an analysis of reports of drug induced mania, psychosis and hallucinations_
(http://jannel.se/strattera.mhra.March.08.pdf) [9] from March 2008.

In the letter from March [9] Eli Lilly’s whitewash report for the period up
to November 2007 is presented. At the end of that report Lilly says [10]:

Nevertheless, Lilly will consider adding language regarding psychotic symptoms
including hallucinations to its product information sheet. (p. 1279)

Larsson – _Suicides & Psychiatric Drugs_
(http://www.newmediaexplorer.org/sepp/suicide.psychiatricdrugs.pdf)

And so we come to October 2008 and the letters from Professor Kent Woods and
from the Scientific Assessor for Strattera. We are reassured that the MHRA
is acting to ensure that Strattera is used as safely as possible that

all safety concerns are subject to robust scientific assessment and the best
possible regulatory action, that any new safety signals are evaluated in
an independent, scientifically robust manner (Woods); we are told that

discussions between European Member States and Eli Lilly are ongoing to agree
on the most appropriate information to be included in the product information
for patients and prescribers; we are told to be patient, to understand that
it takes time from the point where œupdates have been agreed for inclusion in
the product information to the point where these will appear in the packs
in the market place due to movement of stock in the supply chain, and that
the appearances are estimated to be within the next 6 months (Scientific
Assessor).

It is probably hard to find a more obvious violation of the promise¦ we
take any necessary action to protect the public promptly if there is a
problem than the case described above. The worried parents still have no answers if
Strattera can induce the symptoms they find in their children. And the MHRA
knew about it three years ago but withheld the data. This should be
included in the investigation of the agency by the Department of Health.

Strattera causing hyperactivity“ the condition it was supposed to alleviate In my earlier letter to the Department of Health (29th August) I took up the data about the 700 forgotten cases of hyperactivity. I referred to my _letter 2nd January to the MHRA_
(http://jannel.se/letter.mhra.strattera.jan08.pdf) [8] and gave data about the
fact that Eli Lilly had withheld sensitive information and classified harmful effects as an exacerbation of the underlying ADHD.

The logical solution would have been for the MHRA to request all data about
this security risk, followed by an independent review of the data. But this
was not done and as expected nothing is still done. MHRA asked Lilly for an
explanation about this signal stemming from Periodic Safety Update Report
5 (dates 27-05-2005 to 26-11-2005) but got no answer. Three years later the
Scientific Assessor from the MHRA writes in the letter from 1st October:

The information submitted by the MAH [Market Authorization Holder] has been
evaluated and the MAH will be requested to provide further detailed
information within the next 2 months to ensure the issue has been investigated
in a thorough and scientific manner. (p. 2) [3]

The MHRA got this safety signal almost three years ago and is still in
the process of getting some sensible answers from Eli Lilly.

————

I again request the Department of Health to take action. This does not
concern only the children in UK; it concerns the children in the whole of
Europe, indeed it concerns all the children of the world.

The failure of the agency will also mean that psychiatrists within The
Guideline Development Group in NICE can push through more treatment with
Strattera and other ADHD drugs. The MHRA is withholding the clear evidence for
harmful effects and the psychiatrists with close relations to the manufacturers
of the drugs can unimpeded recommend these medicines to unsuspecting
doctors and parents.

The answers given by Professor Kent Woods and the Scientific Assessor did
not in any way handle my concerns. On the contrary, they finally proved that a
full formal investigation of the matters raised above is needed.

Yours sincerely,

Janne Larsson

Reporter – investigating psychiatry
Sweden
_janne.olov.larsson@…_ (mailto:janne.olov.larsson@…)

[1] MHRA, About us, _http://www.mhra.gov.uk_ (http://www.mhra.gov.uk/)
[2] Larsson, Strattera: Eli Lilly gave false information about deaths from
Strattera treatment“ a request for full investigation, May 15, 2008,
_http://jannel.se/Strattera.death2.pdf_ (http://jannel.se/Strattera.death2.pdf)
[3] MHRA, Re: letter of 9th September 2008 to “Assessor responsible for
Strattera, October 1, 2008,
_http://jannel.se/Reply.from%20MHRA.Assessor.October.pdf_
(http://jannel.se/Reply.from%20MHRA.Assessor.October.pdf)
[4] MHRA, Re: Open letter to Pr. Kent Woods (10th August 2008), October 7,
2008
_http://jannel.se/answer.kent.woods.pdf_
(http://jannel.se/answer.kent.woods.pdf)
[5] FDA, Psychiatric Adverse Events Associated with Drug Treatment of ADHD:
Review of Postmarketing Safety Data, released March 3, 2006.
_http://www.fda.gov/ohrms/dockets_
(http://www.fda.gov/ohrms/dockets/AC/06/briefing/2006-4210b_11_01_AdverseEvents.\
pdf
)
[6] MHRA, answer FOI request, May 25, 2007,
_http://jannel.se/mhraanswer.pdf_ (http://jannel.se/mhraanswer.pdf)
[7] Daily Mail, Heart attacks and suicides… yet the dangers were all kept
so quiet. So how CAN you trust your medicine? July 7, 2008,
_http://www.dailymail.co.uk/_
(http://www.dailymail.co.uk/health/article-1033132/Side-effects-include-suicide-\
heart-attacks-So-prescribed-drugs.html
)
[8] Larsson, The ADHD drug Strattera – actions needed now, January 2, 2008,
_http://jannel.se/letter.mhra.strattera.jan08.pdf_
(http://jannel.se/letter.mhra.strattera.jan08.pdf)
[9] Larsson, The ADHD drug Strattera – an analysis of reports of drug
induced mania, psychosis and hallucinations, March 9, 2008,
_http://jannel.se/strattera.mhra.March.08.pdf_
(http://jannel.se/strattera.mhra.March.08.pdf)
[10] Eli Lilly, Cumulative review of Spontaneous Case Reports of Mania,
Psychotic Disorders, Hallucinations, and Agitation, Appendix 16 to Periodic
Safety Report 9 for Strattera, 2008,
_http://jannel.se/Lilly_psychosis_strattera.pdf_
(http://jannel.se/Lilly_psychosis_strattera.pdf)

See also:

_Doctors told to curb use of Ritalin in hyperactive children_
(http://www.timesonline.co.uk/tol/news/uk/science/article4813727.ece)
_Children’s suicide attempts raise concerns about ADHD medication_
(http://www.theglobeandmail.com/servlet/story/RTGAM.20080703.wadhd03/BNStory/spe\
cialScie

nceandHealth/home)
_The ADHD drug Strattera: Lilly to issue warnings about psychosis,
hallucinations, mania and agitation_ (http://jannel.se/strattera.psychosis.doc)
_Strattera side effects_ (http://www.bonkersinstitute.org/stratteraffex.html)

_Strattera – 10,988 adverse “psychiatric reactions” reported in less than
three years_ (http://www.24-7pressrelease.com/view_press_release.php?rID=16662)
_Attention Deficit Hyperactivity Disorder? No, they’re just naughty, say
experts_
(http://www.dailymail.co.uk/news/article-1031436/Attention-Deficit-Hyperactivity\
-Disorder-No-theyre-just-naughty-say-experts.html#
)

471 total views, no views today

10 Year Old Son Committed Suicide while Taking Effexor

“Most doctors don’t even have a clue about this stuff!”

He was 10. Red headed, brown-eyed, full of life and laughter. His doctor spent 10 minutes with him and prescribed Effexor XR….said they would “ramp up” from 37.5 mg to 225 mg at which time his symptoms of ADHD would disappear.

They were RIGHT. Our son took 225 mg for exactly one day. We found him hanging in his closet by the belt of his new bathrobe that same night. Total time on Effexor: 27 days, each ramp up worse than the last in side effects. We were never told by the doctor nor the nurse that this drug could cause suicide or other very serious side effects.

We were never told to watch him closely. All I can say is don’t give this medication to your children unless you have all the facts, have been educated and feel you are making an educated decision for your child. Most doctors don’t even have a clue about this stuff! If I knew then what I know now, he would have NEVER been on Effexor or any other drug.

Please help us fight for complete transparency in the FDA and push for the pharmaceutical companies’ complete disclosure of all studies, both positive and negative. It is the only way we will ever be informed parents. Please do not let my son’s death be only for the pharmaceutical companies’ gain. Be informed or refuse the drug outright.

Be SAFE, your kids are depending on you.

d.eriksson@comcast.net
Richardson, TX

570 total views, no views today

Victim of Adderal Abuse

“My story just proves how ignorant psychiatrists are.”

I have been on a few different anti-depressants in the past two years. I started abusing drugs, mainly Adderal, exactly 2 years ago. This led to me getting “depression”. My mom took me to 3 different psychiatrists. The first one put me on Celexa. For a week all I could do was lay on the couch staring outside with tears in my eyes. We went back and they tried me on Effexor XR. It seemed to work, so they continually increased the dose. The doctor was even convinced I had ADHD and gave me a prescription to Adderal, my drug of choice. Eventually we changed psychiatrists. The Effexor was not working anymore, and he decided to try me on Paxil. I was on a high dose of Effexor which he told me to immediately stop taking, and to start taking Paxil the next day.

This naturally sounds like a bad idea, but I listened to him. I experienced what seemed to be an electric storm going on throughout my body. Every time I moved my eyes I would get this shocking pulse from my head down and everything would go blurry for a fraction of a second. Eventually these all went away. It took approximately a month. A year went by where the only thing that seemed to help me was my addiction to abusing drugs.

Hid this well from my parents, and they AND the doctor believed the Paxil was helping. Well a few months ago I was caught by the police abusing Adderal and my parents were obviously informed. I then went to the psychiatrist so we could all talk. At this point, I was high off of 40 mg’s of OxyContin. The psychiatrist had no idea I was on anything, and proceeded to prescribe me the drug I was addicted to for “my ADHD”. I have been clean from all drugs for 8 days now, and feel much happier. I stopped taking the Paxil a few days ago,25 mg’s a day I was on, and am once again experiencing these shocks. I feel sick and am having trouble keeping food down. But I know I have to sit and wait it out. My story just proves how ignorant psychiatrists are and seem to have no clue what their medications or themselves are doing to have not even had a clue what was going on.

403 total views, no views today